Studies
The record, reconciled.
Where more than one figure is in circulation, this is where we sort out what the primary sources actually say.
- 12 birth control formulations, ranked by meningioma risk A Danish government study tested 12 contraceptive formulations against meningioma risk. Four showed no signal at all. Here's the full table. Updated July 19, 2026
- Depo-Provera adverse-event reports: 4 to 1,845 FDA reports naming Depo-Provera and meningioma rose sharply since 2023. Here's what the data shows, and why it's a reporting surge, not a disease surge. Updated July 19, 2026
- Europe's 15-month head start on the FDA warning European regulators concluded the depo shot's meningioma risk in September 2024. The FDA didn't add its own warning until December 2025. Here's the timeline. Updated July 19, 2026
- What is the depo shot, and why is it in a lawsuit? The depo shot is Depo-Provera, the injectable birth control shot now linked to meningioma risk in two peer-reviewed studies. Here's what the science shows. Updated July 18, 2026
- Why three Depo-Provera meningioma risk numbers differ BMJ says 5.55 times. JAMA Neurology says 2.43 times. A Danish study says 4.55 times. Here's why, and what the numbers actually mean for you. Updated July 18, 2026
- The Depo-Provera case count is still climbing MDL 3140's official pending-case count hit 5,830 on July 1, 2026. Here's what the court's own filings show, and what it means for you. Updated July 1, 2026